Drug Profile
Lomibuvir
Alternative Names: VCH-222; VX-222Latest Information Update: 29 Jul 2016
Price :
$50
*
At a glance
- Originator ViroChem Pharma
- Developer Vertex Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 26 Jul 2016 Trek Therapeutics acquires lomibuvir from Vertex Pharmaceuticals
- 15 May 2014 Vertex Pharmaceuticals completes a phase II trial in Hepatitis C (treatment-naive, combination therapy) in USA, Canada, Germany, Poland and United Kingdom (NCT01516918)
- 01 Feb 2014 Vertex Pharmaceuticals terminates phase II ZENITH trial in Hepatitis C (treatment-naive, in combination with telapravir) in US and New Zealand (NCT01080222)